December 15, 2011
Eisai Co., Ltd.

EISAI'S INDIAN MANUFACTURING BASE RECEIVES APPROVAL FROM U.S. FDA TO MANUFAC ALZHEIMER'S DISEASE TREATMENT ARICEPT®

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) is pleased to announce that its Indian manufacturing and process research base, Eisai Pharmatechnology & Manufacturing Pvt. Ltd. (Location: Andhra Pradesh, India; "EPM"), received approval from the U.S. Food and Drug Administration (FDA) on October 28, 2011 to manufacture both Aricept® 5mg and 10mg film-coated tablets and donepezil hydrochloride active pharmaceutical ingredient (API).

EPM submitted a Prior Approval Supplement (PAS) to the FDA on July 29, 2011 and received approval within one week of a prior approval inspection that was carried out at the facility in October, a record achievement for any pharmaceutical company in India. This approval represents the significant progress that has been made at EPM in the two years since it commenced fully-fledged operations. Currently, EPM manufactures APIs and finished formulations of the muscle relaxant Myonal® Tablets and Aricept® Tablets, from API.

As a global manufacturing and process research base, EPM will make contributions to increasing the benefits provided to patients and their families worldwide by ensuring the stable supply of high quality medicines that are tailored to the diversified needs of each region, in line with its *human health care (hhc)* mission.